MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze AZN →
    • FindStock Picks / Stock Screener
    • Value · AZNIntrinsic Value Calculator
    • Invest · AZNInvestment Case
    • Hold · AZN5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
AZN stock logo

AZN

AstraZeneca PLC

$184.45
0.07
 (0.04%)
Exchange:  NYSE
Market Cap:  286.058B
Shares Outstanding:  1.55B
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – GeneralView industry performance
   
CEO:  Pascal Claude Roland Soriot
Full Time Employees:  96100
Address: 
1 Francis Crick Avenue
Cambridge
CA
CB2 0AA
GB
Website:  https://www.astrazeneca.com
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company’s extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

AZN full analysis

08/02/2026

Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of AstraZeneca, ticker AZN, one of the heavyweights in the global pharmaceutical space. If you’re looking to understand what makes this company tick, whether it’s a solid investment for your portfolio, or just curious about its future prospects, you’re in the right place. Let’s break it all down together, so stick around and let’s get started! Alright, before we get into the nitty-gritty, let’s set…

Open MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
AZAZN logoAZNAstraZeneca PLC286.1B25.918.013.1%
NVNVS logoNVSNovartis AG303.1B30.818.014.0%
AMAMGN logoAMGNAmgen Inc.251.9B26.819.815.6%
GIGILD logoGILDGilead Sciences, Inc.208.5B——28.0%
MRMRK logoMRKMerck & Co., Inc.364.3B14953.24.4%
NVNVO logoNVONovo Nordisk A/S184.4B10.912.330.2%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/10/30 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue45,811,00054,073,00058,739,000
Gross Profit37,543,00043,866,00048,106,000
EBITDA13,422,00015,438,00019,829,000
Operating Income8,193,00010,003,00013,743,000
Net Income5,955,0007,035,00010,255,000

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets101,119,000104,035,000114,074,000
Total Liabilities61,953,00063,164,00065,355,000
Total Stockholders Equity39,143,00040,786,00048,667,000
Total Debt28,622,00030,114,00029,703,000
Cash and Cash Equivalents5,840,0005,488,0005,711,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow10,345,00011,861,00015,191,507
Capital Expenditure-3,778,000-4,586,000-2,810,000
Free Cash Flow6,567,0007,275,00011,765,000
Net Income6,899,0008,691,00010,225,000
Net Change in Cash-346,000-208,000237,825

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)78,715,155.204Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)83,168,354.773Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)81,472,875Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)41,620,531.052Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)44,168,041.544Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)43,198,126.732Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)23,988,774.275Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)25,771,781.656Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)25,092,936.456Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)30,590,779.917Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)32,321,410.411Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)31,662,502.372Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)16.060Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)16.500Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)15.360Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)11Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)5Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
54.073B  ?P/S
 (TTM)
: 
4.59
?Net Income
 (TTM)
: 
7.035B  ?P/E
 (TTM)
: 
25.94
?Enterprise Value
 (TTM)
: 
312.581B  ?EV/FCF
 (TTM)
: 
34.35
?Dividend Yield
 (TTM)
: 
1.71%  ?Payout Ratio
 (TTM)
: 
45.08%
?ROE
 (TTM)
: 
22.31%  ?ROIC
 (TTM)
: 
13.08%
?Net Debt
 (TTM)
: 
24.641B  ?Debt/Equity
 (TTM)
: 
0.66
?P/B
 (TTM)
: 
5.57  ?Current Ratio
 (TTM)
: 
1.01

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
17.98Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Robust Financial Performance: AZN demonstrates strong revenue growth and consistent net income as per the latest income statements, supported by positive free cash flow trends from cash flow statements. This indicates operational efficiency and financial stability, critical for sustaining long-term growth.
  • Innovative Product Portfolio: Insights from earnings call transcripts and news highlight AZN’s focus on innovation in key therapeutic areas, driving revenue as evidenced by product segment data. This positions the company favorably within the pharmaceutical industry.
  • Strong Market Position: With a competitive market cap and a solid presence in the global healthcare sector (as per company profile data), AZN benefits from brand recognition and a large employee base, enhancing its operational capacity.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates AZN intrinsic value between $171.14 – $214.60 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate AZN Intrinsic Value

Common questions about AZN valuation

Is AstraZeneca PLC (AZN) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for AstraZeneca PLC (AZN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is AZN a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AZN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is AZN’s P/E ratio?

You can see AZN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for AZN?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is AZN a good long-term investment?

Whether AZN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for AstraZeneca PLC

  • AstraZeneca PLC intrinsic value calculatorEstimate what the business is worth
  • AstraZeneca PLC 5-year outlookWhat has to go right, and what could go wrong
AZN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.04
MarketSnap

Trading Metrics:

Open: 184.77   Previous Close: 184.38
Day Low: 183.94   Day High: 186.15
Year Low: 153.41   Year High: 212.71
Price Avg 50: 168.41   Price Avg 200: 180.19
Volume: 1.85M   Average Volume: 3.335M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
13-11-2026 18:39
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
EU panel backs AstraZeneca hypertension drug baxdrostat
13-11-2026 09:04
EU panel backs AstraZeneca hypertension drug baxdrostat
AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline
11-11-2026 09:38
AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline
AstraZeneca Plc (NYSE:AZN) Stock Has Average Price Target of $206.67 According to Brokerages
06-11-2026 02:45
AstraZeneca Plc (NYSE:AZN) Stock Has Average Price Target of $206.67 According to Brokerages
FTSE 100 set for monthly gains; AstraZeneca up after results
30-10-2026 06:17
FTSE 100 set for monthly gains; AstraZeneca up after results
AstraZeneca Posts Revenue, Profit Growth on Strong Cancer-Drug Sales
30-10-2026 03:38
AstraZeneca Posts Revenue, Profit Growth on Strong Cancer-Drug Sales

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze AZN →
    • FindStock Picks / Stock Screener
    • Value · AZNIntrinsic Value Calculator
    • Invest · AZNInvestment Case
    • Hold · AZN5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.